Maxitrol, eye drops 5 ml

Maxitrol – antibacterial topical, anti-inflammatory topical.

Pharmacodynamics

Neomycin – has a bactericidal effect by disrupting protein synthesis in the microbial cell. It is active against Staphylococcus aureus, Corynebacterium diphtheriae, Streptococcus viridans, Escherichia coli, Clersella pneumoniae, Proteus vulgaris, Aerobacter aerogenes, Haemophilus influenzae. Little effective against streptococci as well. It is not effective against pathogenic fungi, viruses, anaerobic flora. Microorganisms develop resistance to neomycin slowly and to a small extent.

Polymyxin B. Mechanism of action is caused mainly by blockade of cytoplasmic membrane permeability of bacterial cells. It is active against P. aeruginosa, Aerobacter aerogenes, Escherichia coli, Kiersella pneumoniae, Koch-Weeks bacillus.

Dexamethasone is a GCS. It has anti-inflammatory, anti-allergic and desensitizing effects. It has an anti-exudative effect. Dexamethasone effectively suppresses inflammatory processes.

The combination of dexamethasone with antibiotics reduces the risk of developing an infectious process.

Pharmacokinetics

When used topically, systemic absorption is low.

Indications

Infections of the eyes and its appendages:

blepharitis,
conjunctivitis;
keratoconjunctivitis;
keratitis;
iridocyclitis;
prevention of postoperative inflammation of the anterior part of the eye.

Pharmacological effect

Maxitrol – local antibacterial, local anti-inflammatory.

Pharmacodynamics

Neomycin – has a bactericidal effect, disrupting protein synthesis in the microbial cell. Active against Staphylococcus aureus, Corynebacterium diphtheriae, Streptococcus viridans, Escherichia coli, Klersiella pneumoniae, Proteus vulgaris, Aerobacter aerogenes, Haemophilus influenzae. Not very effective against streptococci. Does not affect pathogenic fungi, viruses, anaerobic flora. Resistance of microorganisms to neomycin develops slowly and to a small extent.

Polymyxin B. The mechanism of action is mainly due to the blockade of the permeability of the cytoplasmic membrane of bacterial cells. Active against P. aeruginosa, Aerobacter aerogenes, Escherichia coli, Klersiella pneumoniae, Koch-Weeks bacillus.

Dexamethasone – GCS. It has anti-inflammatory, antiallergic and desensitizing effects. Has an antiexudative effect. Dexamethasone effectively suppresses inflammatory processes.

The combination of dexamethasone with antibiotics can reduce the risk of developing an infectious process.

Pharmacokinetics

When applied topically, systemic absorption is low.

Special instructions

The bottle must be closed after each use.

Active ingredient

Dexamethasone, Neomycin, Polymyxin B

Composition

Active ingredients:

neomycin sulfate 3500 units;

polymyxin B sulfate 6000 units;

dexamethasone 1 mg;

Excipients:

hydroxypropyl methylcellulose – 0.5%,

polysorbate 20;

neutral additives;

distilled water;

Preservative:

benzalkonium chloride – 0.004%.

Pregnancy

There is no sufficient experience with the use of the drug during pregnancy and breastfeeding.

It can be used for the treatment of pregnant women as prescribed by the attending physician, if the expected therapeutic effect exceeds the risk of developing possible side effects. The use of the drug should be interrupted during breastfeeding.

Use in children

The safety and effectiveness of the drug for children have not been established.

Contraindications

individual hypersensitivity to any of the components of this drug;
viral eye diseases (including keratitis caused by herpes simplex, chicken pox);
mycobacterial eye infection;
tuberculous eye diseases;
acute herpes zoster;
fungal eye diseases;
condition after removal of a corneal foreign body;
purulent infection of the mucous membrane of the eye and eyelids caused by neomycin-resistant microorganisms, purulent corneal ulcer.

Prescribe with caution for glaucoma and cataracts.

Side Effects

Local. An allergic reaction, accompanied by itching and swelling of the eyelids, as well as redness of the conjunctiva. Side effects caused by the steroid component: increased intraocular pressure with the possible subsequent development of glaucoma, damage to the optic nerve and visual fields (when using the drug for more than 10 days, monitoring of intraocular pressure is necessary); posterior subcapsular cataract, slowing of the wound healing process. Topical use of steroids for diseases that cause thinning of the cornea or sclera can lead to their perforation.

Secondary infection

The development of secondary infection is observed after the use of combination drugs containing glucocorticosteroids in combination with antibiotics. With long-term use of steroids, fungal infections of the cornea may develop. The appearance of non-healing ulcers on the cornea after long-term treatment with steroid drugs may indicate the development of fungal invasion. Secondary bacterial infection can occur as a result of suppression of the patient’s protective reaction.

Interaction

When used with other local ophthalmic drugs, the interval between their use should be at least 10 minutes.

Interaction with other drugs is currently unknown.

Storage conditions

At a temperature of 8–30 °C. (vertical)

Shelf life

2 years

Manufacturer

Alcon-Couvreur, Belgium